- PA5-11353 - Invitrogen Antibodies MDM2 antibody

Submitted references MicroRNA-101-3p Suppresses Cancer Cell Growth by Inhibiting the USP47-Induced Deubiquitination of RPL11.

Park J, Cho M, Cho J, Kim EE, Song EJ
Cancers 2022 Feb 15;14(4)

Interaction of YAP1 and mTOR promotes bladder cancer progression.

Xu M, Gu M, Zhou J, Da J, Wang Z
International journal of oncology 2020 Jan;56(1):232-242

Temozolomide promotes genomic and phenotypic changes in glioblastoma cells.

Stepanenko AA, Andreieva SV, Korets KV, Mykytenko DO, Baklaushev VP, Huleyuk NL, Kovalova OA, Kotsarenko KV, Chekhonin VP, Vassetzky YS, Avdieiev SS, Dmitrenko VV
Cancer cell international 2016;16:36

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of MDM2 (arrow) using a Mdm2 polyclonal antibody (Product # PA5-11353) in 293 cell lysates (2 µg/lane) either nontransfected (Lane 1) or transiently transfected with the MDM2 gene (Lane 2).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis using a Mdm2 polyclonal antibody (Product # PA5-11353) in mouse lung tissue lysate. Secondary HRP-anti-rabbit was used for signal visualization with chemiluminescence.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis using a Mdm2 polyclonal antibody (Product # PA5-11353) in HepG2 cell lysates (35 µg per lane).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry analysis in formalin-fixed, paraffin-embedded human prostate carcinoma using a Mdm2 polyclonal antibody (Product # PA5-11353), followed by HRP-conjugated secondary antibody and DAB staining.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 6 Long-term TMZ-treated cells have an individual pattern of expression/activation of the EMT markers and signal transduction pathway components. Proteins were evaluated by Western blot analysis with specific antibodies. AKT v-akt murine thymoma viral oncogene homolog 1, ASK1 mitogen-activated protein kinase kinase kinase 5, ERK mitogen-activated protein kinase, MGMT O-6-methylguanine-DNA methyltransferase, MDM2 MDM2 proto-oncogene, E3 ubiquitin protein ligase, PARP poly (ADP-ribose) polymerase 1, Snail snail family zinc finger 1, Slug snail family zinc finger 2

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 MiR-101-3p inhibits cancer cell growth in a p53-dependent manner. ( a , b ) A549 cells were transfected with a miR-101-3p mimic. ( a ) Cell viability was measured at the time indicated by a WST-1 assay. ( b ) For the colony formation assay, cells were cultured for 10 days and stained with crystal violet in a 6-well plate. ( c , d ) H1299 cells were transfected with a miR-101-3p mimic. ( c ) Cell viability was measured at the time indicated by a WST-1 assay. ( d ) For the colony formation assay, cells were cultured for 10 days and stained with crystal violet in a 6-well plate. ( e ) Western blot analysis was performed to detect p53 and MDM2 protein levels in lysates from A549 cells transfected with the miR-101-3p mimic. beta-actin was used as a loading control. ( f ) U2OS cells transfected with the miR-101-3p mimic were treated with CHX (100 mug/mL) at the times indicated. Western blot analysis was conducted to detect p53 protein levels. Quantification of p53 levels was carried out considering the amount of beta-actin protein in each case. The data in parts ( a - d ) and ( f ) represent the mean +- SD (* p < 0.05, t -test). n.s. , non-specific.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 MiR-101-3p increases the interaction between RPL11 and MDM2. ( a ) HEK293T cells were co-transfected with MDM2, HA-RPL11, Flag-USP47, Flag-USP47 C109S , and miR-101-3p mimic. The interaction between MDM2 and HA-RPL11 was detected by immunoblotting after immunoprecipitation with anti-HA agarose beads. The quantification of MDM2 levels in the IP samples was carried out considering the amount of HA in each case of IP samples. ( b ) A549 and H1299 cells were transfected with a miR-101-3p mimic. The interaction between endogenous RPL11 and MDM2, or RPL11 and USP47 was detected by immunoblotting after immunoprecipitation with anti-RPL11 antibody. Quantification of MDM2 or USP47 levels in the IP samples was carried out considering the amount of RPL11 in each case of IP samples. ( c ) HEK293T cells were transfected with siRNA targeting USP47 (USP47i) alone or together with MDM2 and HA-RPL11. The interaction between MDM2 and HA-RPL11 was detected by immunoblotting after immunoprecipitation with anti-HA agarose beads. Quantification of MDM2 levels in the IP samples was conducted considering the amount of HA in each case of IP samples.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 Detection of the interaction between YAP1 and SKP2. (A and B) HT-1376 and J82 cells were transfected with siRNAs-YAP1; then, cells were harvested and subjected to RT-PCR and western blot assays to determine the knockdown efficiency ( ** P

PA5-11353

Antibody data